MedPath
Found 23 clinical trials|View Analysis
Sort by:

Adaptive Variable-Resistance Training in Pediatric Survivors of Acute Lymphoblastic Leukemia

Not Applicable
Completed
Conditions
Acute Lymphoblastic Leukemia
Interventions
Other: Standard physical therapy
Other: Adaptive variable-resistance training
First Posted Date
2024-03-29
Last Posted Date
2024-03-29
Lead Sponsor
Cairo University
Target Recruit Count
62
Registration Number
NCT06338020
Locations
🇸🇦

Ragab K. Elnaggar, Al Kharj, Riyadh, Saudi Arabia

Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia

Phase 2
Not yet recruiting
Conditions
Pediatric Acute Lymphoblastic Leukemia
Interventions
Drug: ALL, High risk
First Posted Date
2023-12-28
Last Posted Date
2023-12-28
Lead Sponsor
Jae Wook Lee
Target Recruit Count
370
Registration Number
NCT06184009
Locations
🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

🇰🇷

Severance Hospital, Seoul, Korea, Republic of

🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

and more 2 locations

Insomnia Prevention in Children With Acute Lymphoblastic Leukemia

Not Applicable
Completed
Conditions
Leukemia
Acute Lymphoblastic Leukemia
Pediatric Acute Lymphoblastic Leukemia
Interventions
Behavioral: Sleep ALL Night
First Posted Date
2023-05-19
Last Posted Date
2024-07-18
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
25
Registration Number
NCT05866887
Locations
🇺🇸

Boston Children's Hospital, Boston, Massachusetts, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Monitoring Minimal Residual Disease(MRD)in Pediatric B-acute Lymphoblastic Leukemia

Recruiting
Conditions
B Acute Lymphoblastic Leukemia
First Posted Date
2021-07-27
Last Posted Date
2021-07-27
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
255
Registration Number
NCT04977895
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

A Roll-over Study to Provide Continued Treatment With Lyophilized Pegaspargase (S95014) in Pediatric Patients With Acute Lymphoblastic Leukemia (ALL)

Phase 2
Completed
Conditions
Acute Lymphoblastic Leukemia
Interventions
Drug: Lyophilized S95014
First Posted Date
2021-07-09
Last Posted Date
2023-12-29
Lead Sponsor
Institut de Recherches Internationales Servier
Target Recruit Count
75
Registration Number
NCT04956666
Locations
🇷🇺

Regional Children Clinical Hospital, Ekaterinburg, Russian Federation

🇷🇺

Children Regional Clinical Hospital, Krasnodar, Russian Federation

🇷🇺

Regional Children Hospital, Nizhny Novgorod, Russian Federation

and more 2 locations

Financial Distress During Treatment for Pediatric Acute Lymphoblastic Leukemia in the United States

Active, not recruiting
Conditions
Acute Lymphoblastic Leukemia
Interventions
Other: Electronic Health Record Review
Other: Interview
Other: Survey Administration
First Posted Date
2021-06-16
Last Posted Date
2024-10-22
Lead Sponsor
Children's Oncology Group
Target Recruit Count
100
Registration Number
NCT04928599
Locations
🇺🇸

Sunrise Hospital and Medical Center, Las Vegas, Nevada, United States

🇺🇸

Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas, Nevada, United States

🇺🇸

Summerlin Hospital Medical Center, Las Vegas, Nevada, United States

and more 38 locations

Pharmacogenomic Analysis in Pediatric Acute Lymphoblastic Leukemia

Completed
Conditions
Acute Lymphoblastic Leukemia, Pediatric
Adverse Drug Event
First Posted Date
2021-02-25
Last Posted Date
2023-02-16
Lead Sponsor
Cipherome, Inc.
Target Recruit Count
80
Registration Number
NCT04770922
Locations
🇺🇸

Stanford University, Stanford, California, United States

Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minimal Residual Disease (MRD)

Phase 1
Recruiting
Conditions
Pediatric ALL, B Cell
Minimal Residual Disease
Interventions
First Posted Date
2020-10-27
Last Posted Date
2022-03-08
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
20
Registration Number
NCT04604691
Locations
🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

Quality of Life in Pediatric Patients With Acute Lymphoblastic Leukemia Receiving Maintenance Chemotherapy

Not Applicable
Recruiting
Conditions
Quality of Life
Interventions
Behavioral: Physical Activity
First Posted Date
2017-04-28
Last Posted Date
2024-03-04
Lead Sponsor
Connecticut Children's Medical Center
Target Recruit Count
25
Registration Number
NCT03132948
Locations
🇺🇸

Connecticut Children's Medical Center, Hartford, Connecticut, United States

Optimizing 6-mercaptopurine Therapy in Pediatric Acute Lymphoblastic Leukemia by Using Allopurinol

Phase 2
Conditions
Lymphoblastic Leukemia, Acute, Childhood
Interventions
Drug: Standard treatment
Drug: Allopurinol
First Posted Date
2017-01-16
Last Posted Date
2017-01-16
Lead Sponsor
Vastra Gotaland Region
Target Recruit Count
60
Registration Number
NCT03022747
Locations
🇫🇮

Dept of Pediatrics and Adolescents, Oulu University Hospital, Box 23, 90029 OYS, Finland, Oulu, Finland

🇸🇪

Childrens' Cancer Centre, Queen Silvias Childrens and Adolescents Hospital, Gothenburg, Sweden

🇸🇪

Linköping University Hospital, Dept of Pediatrics, Linköping, Sweden

© Copyright 2025. All Rights Reserved by MedPath